Millennium Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Millennium Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-415,520	Closed	-$403K	–	3985
2016 Q1	$403K	Sell	415,520 -325,550	-44%	-$318K	﹤0.01%	2629
2015 Q4	$897K	Buy	741,070 +364,006	+97%	+$1.17M	﹤0.01%	2357
2015 Q3	$2.8M	Sell	377,064 -393,612	-51%	-$3.01M	0.01%	1694
2015 Q2	$5.51M	Buy	770,676 +99,519	+15%	+$775K	0.01%	1337
2015 Q1	$5.76M	Buy	671,157 +287,553	+75%	+$2.57M	0.01%	1334
2014 Q4	$3.83M	Sell	383,604 -443,218	-54%	-$3.78M	0.01%	1568
2014 Q3	$8.19M	Buy	+826,822	New	+$12.2M	0.02%	980
2014 Q1	–	Sell	-64,100	Closed	-$1.17M	–	4346
2013 Q4	$1.17M	Sell	64,100 -63,539	-50%	-$1.2M	﹤0.01%	2179
2013 Q3	$3.42M	Sell	127,639 -162,815	-56%	-$3.49M	0.01%	1336
2013 Q2	$5.36M	Buy	+290,454	New	+$5.13M	0.02%	977

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Millennium Management's RPRX Position: Q2 2016 in Review

Millennium Management sold out of Repros Therapeutics Inc. (RPRX) in Q2 2016, closing a stake of 415,520 shares — an estimated $403K sold.

Millennium Management first reported a position in RPRX in Q2 2013 and held it in 10 quarters. The position peaked at $8.19M in Q3 2014. 43 funds tracked by Wall St. Rank hold RPRX as of Q2 2016.

Millennium Management reported no remaining Repros Therapeutics Inc. position as of Q2 2016 after selling out during the quarter.
Millennium Management sold 415,520 Repros Therapeutics Inc. shares in Q2 2016, an estimated $403K.
Millennium Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 10 quarters.
Millennium Management's Repros Therapeutics Inc. position peaked at $8.19M in Q3 2014.
43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2016.

Based on Millennium Management's 13F filing for Q2 2016, filed 15 Aug 2016.